Stem Cell Therapy Market by Treatment Mode (Autologous & Allogeneic), Therapeutic Applications (CNS, CVS, GIT, Wound Healing, Musculoskeletal, Eye, & Immune System) - Regulatory Landscape, Pipeline Analysis & Global Forecasts to 2020

The global stem cell therapy market is estimated to grow at a lower CAGR in developed countries as compared to emerging countries such as China, India, and Korea in the forecast period (2015-2020). Factors such as increasing funding from various governments and private organizations focus on stem cell research by the growing industry, and rising global awareness about stem cell therapies through various organizations are propelling the growth of the stem cell therapy market. However, lack of required infrastructures, ethical issues related to embryonic stem cell, and the difficulties related with the preservation of stem cells are restraining the growth of this market.

In this report, the global stem cell therapy market has been segmented on the basis of mode of therapy (allogeneic and autologous stem cell therapy) and therapeutic applications (eye diseases, metabolic diseases, GIT diseases, musculoskeletal disorders, immune system diseases, CNS diseases, CVS diseases, wounds and injuries, and others). The allogeneic stem cell therapy market is expected to hold the largest share of the global stem cell therapy market by 2015. This large share can be attributed to the launch of the first-in-class stem cell therapy called prochymal (Osiris Therapeutics, Inc., U.S.), for the treatment of acute graft-versus-host disease (GVHD) in children. This allogeneic therapy was approved in New Zealand and Canada, in May 2012.

Additionally, allogeneic stem cell therapy market is expected to grow at a higher CAGR as compared to the autologous stem cell therapy. Factors such as wider therapeutic applications, easier production scale up, and larger number of ongoing clinical trials of allogeneic stem cell therapies compared to autologous stem cell therapies are stimulating its market growth.

Geographically, North America is forecasted to command the largest share of the global stem cell therapy market in 2015, followed by Asia-Pacific. A number of factors such as extensive government funding and increasing grant of orphan drug status for stem cell therapeutics by FDA, and presence of major leading companies are driving the growth of the stem cell therapy market in North America. However, the economic slowdown and unfavorable reimbursement scenario for the stem cell therapy constraints the growth of the market in this region. The Asia-Pacific region is poised to grow at the highest CAGR in the next five years. Factors such as huge patient population base, increasing regulatory support through favorable government policies, strong product pipeline of stem cell therapies, and rising licensing activities are propelling the growth of the stem cell therapy market in the Asia-Pacific region.

Major players such as Mesoblast Ltd. (Australia), Aastrom Biosciences, Inc. (U.S.), Celgene Corporation (U.S.), and StemCells, Inc. (U.S.) are adopting several growth strategies such as new product approvals, partnerships/agreements/collaborations, joint ventures, mergers, and acquisitions in order to keep pace with the evolving industry trends.

Reasons to Buy the Report:

From an insight perspective, this research report focuses on various levels of analysis-industry analysis (pipeline analysis and investor's network), regulatory scenario, and company profiles, which together comprise and discuss the basic views on the competitive landscape, emerging and high growth segments of the stem cell therapy market, high-growth regions and their respective regulatory policies, government initiatives, drivers, restraints, and opportunities. The above mentioned market research data, current market size, and forecast of future trends will help existing players and new entrants to make the necessary decisions regarding the product offerings, geographic focus, change in strategic approach, R&D investments for innovation in products and technologies, and levels of output in order to remain successful.

Comp